米托萘醇治疗恶性黑色素瘤的II期研究。
Mitolactol chemotherapy for malignant melanoma: a phase II study.
作者信息
Malden L T, Coates A S, Milton G W, McCarthy W H, Levi J A, Woods R L, Byrne M J, Reynolds P M, Fox R M, Hedley D W
出版信息
Cancer Treat Rep. 1984 Jul-Aug;68(7-8):1045-6.
PMID:6744338
Abstract
Fifty-one patients (43 evaluable) with malignant melanoma were treated with mitolactol in an intermittent oral schedule. There were four objective tumor responses, all occurring in patients previously treated with dacarbazine.
摘要
51例恶性黑色素瘤患者（43例可评估）接受了米托拉酮间歇性口服治疗。出现了4例客观肿瘤反应，均发生在先前接受达卡巴嗪治疗的患者中。
Zotero 插件